Skip to main content

NGM Bio Announces Appointment of Shelly Guyer to Board of Directors

Written by Customer Service on . Posted in Public Companies.

SOUTH SAN FRANCISCO, Calif., Dec. 05, 2019 (GLOBE NEWSWIRE) — NGM Biopharmaceuticals, Inc. (Nasdaq: NGM), a clinical stage biotechnology company focused on developing transformative therapeutics for patients, today announced the expansion of its Board of Directors with the appointment of Shelly Guyer, who currently serves as Chief Financial Officer (CFO) of Invitae Corporation (NYSE: NVTA).
“We are thrilled to welcome Shelly to our Board of Directors,” said David J. Woodhouse, Ph.D., Chief Executive Officer of NGM Bio. “Shelly brings strong corporate finance and executive leadership experience at pioneering life science companies striving to advance human health, coupled by deep financial expertise from her long tenure in investment banking. We look forward to leveraging her broad industry insights as we continue to grow and advance a pipeline of transformative therapies across a spectrum of therapeutic areas and diseases.”Ms. Guyer said, “I am delighted to join NGM’s Board of Directors, having followed the company’s progress and emergence as an increasingly prolific research and development organization with an impressive clinical stage pipeline. I look forward to working with David, my fellow board members and the NGM management team as we strategically plan for NGM’s future, and as the company simultaneously advances multiple novel investigational medicines to help address serious unmet needs, including its lead clinical candidate, aldafermin, for the treatment of NASH.”   Ms. Guyer has over a decade of experience building and leading strong financial functions as a senior executive in life sciences, as well as domain expertise as an investment banker and venture capitalist. Prior to her current role as CFO of Invitae, a leading medical genetics company, Ms. Guyer served as CFO at the genomic diagnostics company Veracyte, Inc. and as CFO and Executive Vice President of finance and administration at iRhythm Technologies, Inc. She began her business career at Hambrecht & Quist and later J.P. Morgan Securities, where she held various positions, including principal of healthcare banking for the West Coast, leading financings for a variety of large and small cap life science companies. Ms. Guyer holds an AB from Princeton University and an MBA from the Haas School of Business, University of California, Berkeley.  About NGM Biopharmaceuticals, Inc.NGM is a clinical stage biopharmaceutical company focused on developing novel therapeutics based on scientific understanding of key biological pathways underlying cardio-metabolic, liver, oncologic and ophthalmic diseases. The company leverages its biology-centric drug discovery approach to uncover novel mechanisms of action and generate proprietary insights that enable it to move rapidly into proof-of-concept studies and deliver potential first-in-class medicines to patients. NGM aspires to operate one of the most productive research and development engines in the biopharmaceutical industry, with multiple programs in clinical development. Visit http://www.ngmbio.com for more information.

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.